Typical weight loss on Wegovy: separating the headlines from the evidence

The biggest misconception: Wegovy produces a fixed, predictable amount of weight loss

The number people most often quote is 15%. It appears in news articles, on comparison sites, in conversations with friends who've started treatment. And it is real, drawn from the STEP 1 trial, one of the largest and most rigorous semaglutide studies run to date. But treating it as a prediction for any one person misreads what a trial average means.

STEP 1 enrolled over 1,900 adults with obesity or overweight and at least one weight-related condition, none of whom had type 2 diabetes. At 68 weeks, the semaglutide group had lost roughly 15% of starting body weight on average. But the spread around that average was wide. Some participants lost more than 20%. Others lost less than 5%. Age, baseline weight, how consistently treatment was taken, dietary habits, activity, individual metabolism, all of these influenced where someone landed.

The trial was also conducted alongside structured lifestyle support, which most real-world participants don't receive at the same intensity. That matters for context, though it does not mean Wegovy only works in a clinical-trial setting. What it means is that how much weight you lose on Wegovy depends on far more than which medicine you are taking.

If you feel anxious reading that, you're in good company. Most people starting treatment want some sense of what to expect. A realistic range (rather than a single headline figure) is the more honest frame.

How results build over the 68-week treatment period

Wegovy's titration schedule starts at 0.25mg and moves upward (through 0.5mg, 1.0mg and 1.7mg) before reaching the 2.4mg maintenance dose. Each step takes roughly four weeks, which means most people are not at the full dose until around week 16 or 17. Early weight loss in week one is typically modest and largely driven by changes to eating patterns rather than the medicine working at full effect.

The trajectory matters. Trials show that weight loss tends to accelerate once the maintenance dose is established, then continues at a slower rate before plateauing. Most of the headline figure (that 15% average) accumulates across months, not weeks. People who stop at three months will not see what people who complete the full course see. This is one reason clinical guidance, including NICE's appraisal of semaglutide (TA875), builds in a review at six months: if less than 5% weight has been lost by that point at the maintenance dose, continuing is reconsidered.

Understanding that the timeline is long can be reassuring rather than frustrating. Slow early progress does not mean treatment is failing. If you are several weeks in and uncertain about how long Wegovy takes to work, the titration schedule is almost always the explanation.

The 7.2mg dose and what the newer evidence adds

Since the STEP 1 results were published, the evidence picture has shifted. The MHRA approved a higher 7.2mg semaglutide dose (Wegovy) in January 2026 and a dedicated single-dose 7.2mg pen in April 2026. Trial data for this higher dose reported average weight loss of around 20.7% over 72 weeks, considerably more than the 2.4mg standard, and approaching the results seen with tirzepatide (Mounjaro) in its own programme.

The 7.2mg pen is approved for adults with a BMI of 30 or above; the starting dose and titration path remain the same, with 7.2mg as the maximum. Whether this dose becomes the right option for any individual is a clinical question, and specific dose availability is confirmed at consultation rather than assumed. For a fuller picture of how the two licensed injectable options compare on results, the Wegovy weight-loss results page sets out the trial data side by side.

One thing is consistent across the evidence: the people who see the largest reductions are, on the whole, those who take treatment consistently, engage with dietary changes alongside it, and continue through the full titration period. The medicine reduces appetite and slows gastric emptying; it does not do the work in isolation.

What 'typical' weight loss on Wegovy means in practice

A working range for most people completing the full 2.4mg course, based on trial data, is somewhere between 10% and 20% of starting body weight over 12 to 18 months. For someone starting at 90kg, that is 9kg to 18kg. For someone starting at 120kg, it is 12kg to 24kg. These are not guarantees, they reflect where the evidence places the majority of trial participants.

A small number of people do not respond well. If you are concerned you may be in that group, the reasons why some people don't lose weight on Wegovy covers the most common clinical explanations. It is worth reading before drawing conclusions from a short treatment period.

Wegovy is a prescription-only medicine and every course of treatment at nume is reviewed by a real prescriber before it begins and before each repeat. Our Wegovy treatment page explains the full process. On cost, the Wegovy pricing page covers what a legitimate private prescription includes and why the price varies by dose. If you'd like to understand whether you're likely to be eligible, checking your eligibility with our clinical team is free and takes a few minutes.